Novo CEO eyes cheap biotech market: "Of course the price matters, but there are other factors, too"

Big biotech price drops could create acquisition opportunities similar to the firm’s record-breaking purchase of Dicerna, says Novo Nordisk CEO Lars Fruergaard Jørgensen, explaining that the company is looking at a wide range of disease areas for potential purchases.

Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Photo: Stine Bidstrup/ERH

Novo Nordisk expects future research and development expenditures will increase at a higher rate than the company’s top line growth. This will ensure that one or more successors are ready once the pharmaceutical firm’s current growth engine, semaglutide, loses its patent.

As well as internal research, one eye will be fixed on potential acquisition candidates for Novo Nordisk. As late as December 2021, the Danish company bought US-based Dicerna for USD 3.3bn – the single biggest acquisition on Novo’s history.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs